Covid-19 Therapeutics Accelerator has launched with $125m to find treatments for the pandemic, $25m of which came from Mastercard.

Payment services firm Mastercard committed $25m to Covid-19 Therapeutics Accelerator, a US-based drug development accelerator that launched with $125m in seed funding last week. Philanthropic organisation Bill and Melinda Gates Foundation and life science research charity Wellcome Trust have each contributed $50m to the scheme. Covid-19 Therapeutics Accelerator will evaluate existing drugs and look to…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.